Dijia Pharmaceutical Group Co., Ltd.

On Chemball

My Chemball

As Supplier

My RFQ Manage Products

As Buyer

My RFQ Post RFQ

My Account

+86-571-8627 3270

Dijia Pharmaceutical Group Co., Ltd.

11 YRS

Shandong, China

CNY 585 Million

1065600 m²

500-1000 people

Main Products: 2-N-Propyl-4-Methyl-6-(1’-Methylbenzimidazol-2’-Yl)Benzimidazole / 2-(4-Bromomethyl)Phenylpropionic Acid / 6-Carboxy-4-Methyl-2-Propylbenzimidazole / Methyl 2-Oxocyclopentanecarboxylate

Shandong, China

Contact Supplier

Home Company Profile Contact Us Post Buying Request

ABOUT US

Dijia Pharmaceutical Group Co., Ltd. is a subsidiary of Disha Pharmaceutical Group and a national high-tech enterprise. Since its establishment, it has always adhered to the enterprise philosophy of "integrity as the root and customer-oriented". The company mainly produces cardio cerebrovascular, hypoglycemic, hypolipidemic and other pharmaceutical intermediates, APIs and new marine biological materials. As the upstream supporting industrial chain of the preparation sector of Disha Group, the company focuses on developing varieties with high safety, low pollution and high added value. It has an annual production capacity of 1000 tons of API and chemicals, more than 30 kinds of API products, more than 50 kinds of intermediate products and new marine biological materials. The company officially moved to Wendeng chemical park in 2013, with a total planning area of 1600 mu and an existing construction area of 160000 square meters, of which 62000 square meters have been put into use and 98000 square meters are under construction. It will be built into one of the largest API production bases in China. The overall planning is divided into three phases. The first phase of API production project covers an area of more than 500 mu, which has been basically completed and put into use; Phase II high-end API green process industrialization project has been listed as a key project in 2019, with a planned investment of 1 billion yuan, and is now accelerating as planned. Relying on the national enterprise technology center, national postdoctoral workstation and other national R & D platforms of the group company, the company has established Shandong analgesic drug engineering technology research center and Weihai enterprise technology center, with 158 full-time R & D personnel, including 113 with master's degree or above, 59 research projects, of which 58 are independent R & D.

Basic Information